ANR PRC program 2020 is a joint cooperation between ICMUB-DIJON (Prof. Claude GROS), ICPEES, and COBRA

ANR details

MIPEnz-Decontam is a multidisciplinary project aiming at developing innovative decontamination tools able to detoxify, under mild conditions, a broad spectrum of pesticides and chemical warfare agents involved both as vesicants and organophosphorus nerve agents. By a unique combination of established expertise in synthetic organic, smart polymers, supramolecular and macromolecular chemistry, the design of original Molecularly Imprinted Polymers as enzyme mimics based on a recently proven strategy, will allow to provide, for the first time, efficient broad spectrum solutions against the unresolved issues related to the use and the stockpiling of chemical weapons and pesticides. Based on a strong and complementary know-how, well established expertise, and longstanding fruitful collaborations among the three partners, our challenging approach will culminate on the discovery of novel biomimetic MIP to afford effective technologies, with high socio-economic impact in the civilian and military defence.

Principal investigator: Dr Rachid Baati (Institut de Chimie et Procédés pour l'Energie, l'Environnement et la Santé (UMR 7515))

ANR PRC program 2021 a joint cooperation between ICMUB-DIJON (J.-C. Hierso) and LHFA-TOULOUSE (D. Bourissou)

ANR details

CARAPH is a fundamental project aiming at merging the chemistry of carbon materials and Lewis pairs. On the one hand, it seeks to immobilize (P, B)-Lewis pairs on sp2-C materials via pi-pi interactions and to apply these heterogenized FLPs to (de)hydrogenation catalysis. On the other hand, the formation of 1D-sp3 chains (diamondoids) by dative P->B interactions and their application to gas sensing are targeted.

Principal investigator: Prof. Jean-Cyrille HIERSO

Simplified principle of next-generation fluorogenic theranostic agents (fluorogenic pro-drugs) claimed in the InnoTherano project.

In vivo chemistry can be defined as the use of cells as reaction vessels and some of their constituents as catalysts to achieve internal construction of molecular nano-objects from exogenous synthetic precursors. This is a growing research field that is seen as having a great future potential for various applications in the field of diagnosis (based on molecular imaging), therapy and synthetic biology. Our project aims at implementing this attractive concept to the development of next-generation fluorogenic theranostic agents (abbreviated as NG-FTAs) that may be potentially used either for anti-cancer chemotherapy of for treatment of infectious diseases. Thus, we intend to develop novel fluorogenic pro-drugs using an innovative strategy based on in situ formation of an organic-based fluorophore from a caged precursor responsive to a biomarker related to a disease state (typically, an enzyme belonging to the class of glycosidases). This fluorogenic "covalent-assembly" type process will be accompanied by the concomitant release of a drug molecule through a domino reaction also effective in physiological media. A biocompatible intramolecular cyclization reaction leading to in situ formation of a fluorescent pyronin scaffold will be preferred for the two following reasons: (1) facile tuning of spectral features of formed xanthene dye, within the range 520-660 nm (selected according to the targeted application and the related biological context) by modifying alkyl substituents of -NR2 group and/or replacing the intracyclic oxygen atom by CMe2 or SiMe2 moiety (carbo- or Si-pyronins), of caged precursor ; (2) its combined use with modern tools produced by medicinal chemistry (self-immolative molecular platforms developed for pro-drug strategies) should enable the rapid access to NG-FTAs through simple and effective molecular lego® approach. This is an interesting and important feature of the project aimed at rapidly optimizing physico-chemical and pharmacological properties but also fluorescence imaging and therapy performances of NG-FTAs without resorting to tedious and time-consuming de novo syntheses. Our second objective will be to apply this innovative probe design principle to the development of novel dual-functional drug delivery systems (abbreviated as DF-DDSs) for combined pharmaco-photodynamic therapy (i.e., in situ formation of a ROS-generating photosensitizer and drug release). Indeed, these DF-DDSs may be the cornerstone of novel combined therapy strategies assumed as effective ways to overcome for instance, difficulties inherent to chemotherapy or antibiotics resistance. The caged precursor associated to a self-immolative molecular platform for drug delivery, will be designed to generate after enzymatic activation, a sulfur- or a selenium analog of pyronin, poorly or non-fluorescent but acting as an effective photosensitizer for PDT. Again, molecular lego® approach will be key to access to DF-DDS molecules with optimized properties and performances. Even if our prime ambition is advancing the state of knowledge in the research field of in vivo chemistry, rather than address a specific relevant biomedical need, we plan to make validations of these "smart" molecular diagnostic and/or therapeutic tools be means of in vivo models of cancer and bacterial infection. From a practical point of view, some DF-DDS molecules will be tested on surgical prostheses and implants to monitor their microbiological quality and to eradicate bacteria colonies over their surfaces, through a combined "enzyme-prodrug-therapy" (EPT) and PDT strategy (i.e., bimodal synergistic antimicrobial treatment PDT-prodrug).

Principal investigator: Prof. Anthony ROMIEU

Partner: Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), UMR CNRS 7285, "Programmed Molecular Systems" (PMS) group, P.I.: Prof. Sébastien PAPOT, http://smp.labo.univ-poitiers.fr

Other ICMUB members involved in the InnoTherano project: Dr. Richard DECREAU & Dr. Bertrand COLLIN

Starting date: March 2022 (duration: 36 months)

Funding amount: 325 K€

ANR PRC program 2021 is a joint cooperation between ICMUB-DIJON (Prof. Ewen BODIO), LCH Laboratoire de CHimie - ENS Lyon (Prof. Olivier MAURY), IAB Institut pour l'avancée des biosciences (Dr Lucie SANCEY) and ISCR Institut des Sciences Chimiques de Rennes (Dr Boris LE GUENNIC)

ANR details

Optical imaging, long regarded only as an in vitro tool, has recently gained an increasing interest for in vivo applications, especially for surgery assistance. Indeed, fluorescent contrast agents enable an accurate visualization in real time of nerves, vessels, diseased tissues (inflammation, tumor…), which ensure a better recovery for the patient and less relapses. However, most of the reported near infrared-emitting fluorophores – preferable for in vivo imaging – are long to synthesize, difficult to functionalize, display limited stability, and are very poorly soluble in aqueous media. Thus, there is an urgent need for new near-infrared fluorophores for in vivo optical imaging, especially for fluorescence-guided surgery. This project aims at developing a new class of fluorophores and multimodal probes able to meet these needs. More than just new fluorophores, the targeted compounds are likely to present novel and original photophysical and coordination properties.

Principal investigator:  Prof. Ewen BODIO (ICMUB - UMR 6302)

ANR PRC program 2021 is a joint cooperation between ICMUB-DIJON (Dr Michel MEYER), SUBATECH, IC-UNISTRA, GANIL and IJCLab

ANR details

Novel radio-isotopes are important in nuclear medicine to increase possibilities of imaging/therapies, and to better personalize treatments to the different patients. Their development is strongly constrained by the possibility of producing them in sufficient quantity with high chemical and isotopic purity. TTRIP will take the opportunity of an efficient isotope separator for the production of very pure stable Gd-155 as precursor of Tb-155, which in turn is used for SPECT imaging as one of the Tb quadruplet theranostic isotopes. Characterization of this precursor and its irradiation to produce Tb-155 will complete this proof-of-concept experiment. Parametric studies will then be done to find optimal conditions of this whole process of production. In parallel, a bifunctional chelator will be designed and bioconjugated to monoclonal antibodies and nanobodies. The sought bioconjugates should be able to withstand mild 155Tb labeling conditions to avoid the denaturation of the biological vector.

Principal investigator: Mr Charles-Olivier Bacri (Laboratoire de physique des 2 infinis – Irène Joliot-Curie)

L’Europe s’engage en Bourgogne Franche-Comté

Le programme concerne la recherche de nouveaux procédés de synthèse éco-compatibles, et la mise en œuvre de matériaux originaux en vue de l’activation ou la détection de molécules, la séparation d’espèces chimiques stratégiques, ou la dépollution et le recyclage de métaux stratégiques. L’approche qui a été retenue pour répondre à cette demande sociétale majeure de transition écologique/économique se base dans ce projet sur la réactivité métallique et catalytique par chimie de coordination, dont les principes généraux s’appliquent de manière transversale au domaine de la captation chimique et des capteurs au sens large : détection, stockage, relargage, contrôle, quantification, dépollution. Un point clé du projet est l'acquisition d'un équipement d'Instrumentation d'analyse de surface Hard X-ray Photo-électroscopie (HAXPES).

Le projet CoMICS requiert des compétences dans des domaines variés, compétences complémentaires en chimie expérimentale et théorique, chimie moléculaire, réactivité et caractérisation de surface, qui sont réunies en Bourgogne Franche-Comté au travers d’un partenariat fort entre 4 laboratoires des Instituts du CNRS.

NOM DU PROJET : COMICS (Chemistry Of Molecular Interactions Catalysis & Sensors)

PORTEUR DE PROJET: ICMUB UMR CNRS 6302 - Université de Bourgogne (Prof. Jean-Cyrille HIERSO)

MONTANT FEDER (portage UB) : 463 850.00 € HT - Montant total du projet COMICS UBFC : 1 231 600.00 € HT